固体腫瘍におけるサイトカイン放出症候群
David Synnott1,2,3, David O'Reilly1,3,4, Declan De Freitas1,2,4
1Beaumont Hospital, Dublin, Ireland.
Cancer
|August 23, 2025
まとめ
サイトカイン放出症候群 (CRS) は,免疫療法の深刻な副作用です. このレビューは,固体腫瘍におけるCRSを詳細に説明し,患者の改善のためのユニークな課題と管理戦略に焦点を当てています.
科学分野:
- 腫瘍学
- 免疫学
- 薬理学について
背景:
- サイトカイン放出症候群 (CRS) は,CAR T細胞療法や双極性T細胞誘導剤のようながん免疫療法における頻繁な合併症である.
- CRSの現在の管理ガイドラインは主に血液学的悪性腫瘍に対応しており,固体腫瘍については特別な考慮が必要である.
研究 の 目的:
- 固体臓器腫瘍の文脈におけるCRSの病理生理学,臨床表現,および管理をレビューする.
- 固体腫瘍におけるCRSのユニークな課題と複雑さを強調し,腫瘍の微小環境と潜在的な毒性を含みます.
主な方法:
- 固体腫瘍におけるCRSに関する既存の研究の文献レビュー.
- 病理生理学,臨床症状,現在の治療戦略の分析
- 新興治療法と将来の研究方向の議論
主要な成果:
- 固体腫瘍は,免疫抑制的微小環境と潜在的標的外効果のためにユニークなCRS課題を提示します.
- 早期発見と分類は効果的なCRS管理に不可欠です.
- 管理は,軽度の症例のサポートケアから,標的治療 (例えば,トシリズマブ,コルチコステロイド) まで,重症症例のICUサポートまで様々です.
結論:
- 固体腫瘍患者の免疫療法の安全性と有効性を高めるには,個別化された治療方法が必要である.
- リスクの階層化,新しい治療法,長期的な結果に関するさらなる研究が不可欠です.
- 固体腫瘍におけるCRSを理解することで,患者のケアと治療戦略が改善されます.
さらに関連する動画
関連する概念動画
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Regulation of Hematopoietic Stem Cells
3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
Cytotoxic T Cells-mediated Immune Response
1.9K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.9K
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K


